Table I.
Annotated pathways of co-expressing genes of the corresponding differentially expressed lncRNAs.
| lncRNA | Pathway | P-value | Genes |
|---|---|---|---|
| RP1-193H18.2 | hsa04115:p53 signaling pathway | <0.001 | CDKN1A, PPM1D, CASP8, PMAIP1, GADD45B, GADD45A |
| hsa04912:GnRH signaling pathway | 0.005 | JUN, CAMK2D, HBEGF, ITPR1, MAP2K6 | |
| hsa04012:ErbB signaling pathway | 0.020 | CDKN1A, JUN, CAMK2D, HBEGF | |
| hsa04010:MAPK signaling pathway | 0.040 | RPS6KA5, DUSP14, JUN, GADD45B, GADD45A, MAP2K6 | |
| RP11-134G8.8 | hsa04115:p53 signaling pathway | <0.001 | CDKN1A, PPM1D, TP53I3, EI24, LRDD, DDB2, SFN, GADD45A |
| hsa05219:bladder cancer | 0.080 | HRAS, CDKN1A, PGF | |
| hsa00561:glycerolipid metabolism | 0.090 | CEL, AKR1B1, LIPC | |
| RP11-363E7.4 | hsa04115:p53 signaling pathway | <0.001 | LRDD, ZMAT3, RRM2B, SFN, PMAIP1, SESN1, RFWD2, EI24, TP53I3, PPM1D, CDKN1A, CCND3, CASP8, DDB2, MDM2, FAS, PERP, GADD45A |
| hsa00970:aminoacyl-tRNA biosynthesis | 0.003 | PSTK, FARS2, NARS2, HARS2, LARS2, DTD1 | |
| hsa04110:cell cycle | 0.038 | ANAPC1, CDKN1A, CCND3, ANAPC1P1, MDM2, SFN, GADD45A, TUBB2A, TUBB6, | |
| hsa04540:Gap junction | 0.040 | TUBA4A, ITPR1, MAP2K5 | |
| hsa04120:ubiquitin mediated proteolysis | 0.050 | RFWD2, ANAPC1, FBXW7, ANAPC1P, TRIM32, DDB2, MDM2, NKD1, CSNK2A1, | |
| hsa04310:Wnt signaling pathway | 0.070 | CCND3, PPP2CB, CSNK2A1P, NFATC2, TBL1X | |
| RP11-612B6.2 | hsa03018:RNA degradation | 0.090 | EXOSC4, CNOT2, ZCCHC7 |
lncRNA, long noncoding RNA; hsa, Homo sapiens; CDKN1A, cyclin-dependent kinase inhibitor 1A; PPM1D, protein phosphatase, Mg2+/Mn2+ dependent 1D; CASP8, caspase 8, apoptosis-related cysteine peptidase; PMAIP1, phorbol-12-myristate-13-acetate-induced protein 1; GADD45B, growth arrest and DNA damage inducible beta; GADD45A, growth arrest and DNA damage inducible alpha; JUN, Jun proto-oncogene; CAMK2D, calcium/calmodulin dependent protein kinase II delta; HBEGF, heparin binding EGF-like growth factor; ITPR1, inositol 1,4,5-trisphosphate teceptor type 1; MAP2K6, mitogen-activated protein kinase kinase 6; RPS6KA5, ribosomal protein S6 kinase A5; DUSP14, dual specificity phosphatase; TP53I3, tumor protein P53 inducible protein 3; EI24, EI24, autophagy associated transmembrane protein; LRDD, P53-induced death domain protein 1; DDB2, damage specific DNA binding protein 2; SFN, stratifin; HRAS, Harvey rat sarcoma viral oncogene homolog; PGF, placental growth factor; CEL, carboxyl ester lipase; AKR1B1, aldo-keto reductase family 1, member B1; LIPC, lipase C, hepatic type; ZMAT3, zinc finger matrin-type 3; RRM2B, ribonucleotide reductase regulatory TP53 inducible subunit M2B; SESN1, sestrin 1; RFWD2, ring finger and WD repeat domain 2; CCND3, cyclin D3; ANAPC1P1, anaphase promoting complex subunit 1 pseudogene 1; MDM2, MDM2 proto-oncogene; FAS, Fas cell surface death receptor; PERP, PERP, TP53 apoptosis effector; PSTK, phosphoseryl-tRNA kinase; FARS2, phenylalanyl-tRNA synthetase 2, mitochondrial; NARS2, asparaginyl-tRNA synthetase 2, mitochondrial (putative); HARS2: histidyl-tRNA synthetase 2, mitochondrial; LARS2, leucyl-tRNA synthetase 2, mitochondrial; DTD1, D-tyrosyl-tRNA deacylase 1; ANAPC1, anaphase promoting complex subunit 1; TUBB2A, tubulin teta 2A class IIa; TUBB6, tubulin beta 6 class V; TUBA4A, tubulin alpha 4a; ITPR1, inositol 1,4,5-trisphosphate receptor type 1; MAP2K5, mitogen-activated protein kinase kinase 5; FBXW7, F-box and WD repeat domain containing 7; TRIM32, tripartite motif containing 32; NKD1, naked cuticle homolog 1; CSNK2A1, casein kinase 2 alpha 1; PPP2CB, protein phosphatase 2 catalytic subunit beta; CSNK2A1P, casein kinase 2 alpha 3; NFATC2, nuclear factor of activated T-cells 2; TBL1X, transducin (beta)-like 1X-linked; EXOSC4, exosome component 4; CNOT2, CCR4-NOT transcription complex subunit 2; ZCCHC7, zinc finger CCHC-type containing 7.